5-ALPHA REDUCTASE INHIBITORS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA DOES NOT INCREASE THE RISK OF ERECTILE DYSFUNCTION

被引：0
|
作者：
Hagberg, Katrina
Divan, Hozefa
Persson, Rebecca
Jick, Susan
Nickel, J. Curtis
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.juro.2017.02.325
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP09-17
引用
收藏
页码：E106 / E107
页数：2
相关论文
共 50 条
  • [1] Risk of Erectile Dysfunction Associated with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Persson, Rebecca
    Nickel, J. Curtis
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 465 - 466
  • [2] The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
    Kim, Eric H.
    Brockman, John A.
    Andriole, Gerald L.
    ASIAN JOURNAL OF UROLOGY, 2018, 5 (01) : 28 - 32
  • [3] Risk of Gynecomastia with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Nickel, J. Curtis
    Fang, Shona
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 531 - 532
  • [4] Cardiovascular risk among benign prostatic hyperplasia patients receiving alpha blockers and 5-alpha reductase inhibitors
    Olawore, Oluwasolape
    Latour, Chase
    Zhang, Jiandong
    Pate, Virginia
    Sturmer, Til
    Friedlander, David
    Funk, Michele Jonsson
    Jensen, Brian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 571 - 572
  • [5] Long-term treatment of Benign Prostatic Hyperplasia with the combination of alpha blockers and 5-alpha reductase inhibitors
    Ozer, Cevahir
    Tekin, Mehmet Ilteris
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (04): : 263 - 266
  • [6] The Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures
    Lim, Sian Yik
    Laengvejkal, Pavis
    Panikkath, Ragesh
    Nugent, Kenneth
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 463 - 471
  • [7] 5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA
    Wallner, Lauren
    DiBello, Julia
    Li, Bonnie
    Van Den Eeden, Stephen
    Weinmann, Sheila
    Ritzwoller, Debra
    Abell, Jill
    D'Agostino, Ralph, Jr.
    Loo, Ronald
    Aaronson, David
    Richert-Boe, Kathryn
    Horwitz, Ralph
    Jacobsen, Steven
    JOURNAL OF UROLOGY, 2016, 195 (04): : E27 - E28
  • [8] 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia
    Wallner, Lauren P.
    DiBello, Julia R.
    Li, Bonnie H.
    Van Den Eeden, Stephen K.
    Weinmann, Sheila
    Ritzwoller, Debra P.
    Abell, Jill E.
    D'Agostino, Ralph, Jr.
    Loo, Ronald K.
    Aaronson, David S.
    Richert-Boe, Kathryn
    Horwitz, Ralph I.
    Jacobsen, Steven J.
    MAYO CLINIC PROCEEDINGS, 2016, 91 (12) : 1717 - 1726
  • [9] Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Fang, Shona C.
    Nickel, J. Curtis
    Jick, Susan S.
    CLINICAL EPIDEMIOLOGY, 2017, 9 : 83 - 91
  • [10] 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection
    Erdemir, Fikret
    Harbin, Andrew
    Hellstrom, Wayne J. G.
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (12): : 2917 - 2924
12345